Updated JCVI Guidance – Covid vaccination of children and young people aged 12- 17 years

by BSPGHAN | Aug 22, 2021 | News

Dear members

Please see updated Guidance from the JCVI

https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years

in addition to previous advice

https://www.gov.uk/government/publications/covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-jcvi-statement

At this time,

• the Pfizer-BioNTech BNT162b2 vaccine is the only vaccine authorised for persons aged 12 to 17 years in the UK
• JCVI advises that all 16 to 17-year-olds should be offered a first dose of Pfizer-BNT162b2 vaccine. 
• Persons aged 12 to 15 years with specific underlying health conditions that put them at risk of severe COVID-19, should be offered 2 doses of Pfizer-BNT162b2 vaccine with an interval of 8 weeks between doses.

This currently includes children with severe neuro-disabilities, Down’s Syndrome, underlying conditions resulting in immunosuppression, profound and multiple learning disabilities (PMLD), severe learning disabilities or who are on the learning disability register. Details regarding additional person-groups with underlying health conditions to be offered vaccination will be provided as updates in the Green Book.

Children and young people aged 12 years and over who are household contacts of persons (adults or children) who are immunosuppressed should be offered 2 doses of Pfizer-BNT162b2 vaccine.

The rollout of Covid vaccination in England will be led through primary care. The letter notes: “We recognise that not all eligible 12-15 year olds may be identified through the GP record. Therefore, any approach by parents of children at increased risk should be considered and clinical judgement used around eligibility in line with JCVI advice. In addition, trusts may refer 12-15 year olds for a COVID-19 vaccination if they consider them to be eligible”

Letter to primary care –
https://www.england.nhs.uk/coronavirus/publication/covid-19-vaccination-programme-actions-for-all-practices-to-support-vaccinating-eligible-12-15-year-olds/

FAQs on Vaccination delivery operations
https://www.england.nhs.uk/coronavirus/publication/vaccinating-children-and-young-people-faq

Best wishes

Sue

Dr S Protheroe
BSPGHAN President

Updated JCVI advice on Covid19 vaccines for adults aged under 30 years

by BSPGHAN | Apr 7, 2021 | News

Covid19 Vaccination update 7^th April 2021

(replaces advice on BSPGHAN website on 31^st January 2021)

Today, April 7^th, 2021, the Joint Committee on Vaccination and Immunisation (JCVI) has changed their clinical advice on Covid 19 vaccines for those aged under 30 years.  

Adults aged 18 to 29 who do not have an underlying health condition that puts them at greater risk from Covid should be offered an alternative to the Astra Zeneca vaccine if one is available.

The MHRA advised that-

• side-effects were "extremely rare" - and more work was going on to identify if the Astra Zeneca vaccine was causing blood clots.
• People who have had their first dose of the AstraZeneca vaccine should still get their second dose. 
• Only those who suffered one of these rare blood clots after the first dose should not get vaccinated.
• People with blood disorders that leave them at risk of clotting should discuss the benefits and risks of vaccination with their doctor.
• The JCVI today said that they have not made a  decision yet  (on vaccine advice) on those aged under 18 years.

The Pfizer/BioNTech vaccine is authorised for use in individuals aged 16 years and over, and the Oxford/AstraZeneca vaccine is authorised for individuals aged 18 years and over. 

Also see that here that the RCPCH updated their advice on 29^th March 2021, for paediatricians on children and young people and the COVID-19 vaccination programme https://www.rcpch.ac.uk/news-events/news/message-paediatricians-children-young-people-covid-19-vaccination-programme

This advice may be updated in light of the announcement today.

We are now in the first phase of the programme during which young people (aged 16 years and over) with specific clinical vulnerabilities will be offered vaccination^.1   ( Based on JCVI advice, individuals aged 16–65 years in at-risk groups are eligible for immunisation in Phase 1 of the programme).

The Green Book says: “Children and young people have a very low risk of COVID-19, severe disease or death due to SARS-CoV-2 compared to adults and so COVID-19 vaccines are not routinely recommended for children and young people under 16 years of age. Children under 16 year of age, even if they are CEV, are at low risk of serious morbidity and mortality, and, given the absence of safety and efficacy data on the vaccine, are not recommended for vaccination.” ²

While this is the case, vaccinations should not be offered to children and young people who fall outside the categories advised by the JCVI and the Green Book.  

The only other group identified by the Joint Committee on Vaccination and Immunisation (JCVI) and the Green Book³ that may be considered for the vaccine during phase 1 are:

• older children (aged 12 years and over) with severe neuro-disabilities and recurrent respiratory tract infections who frequently spend time in specialised residential care settings for children with complex needs.

Such vaccinations would be considered unlicensed use.⁴ Paediatricians should discuss the benefits and risks and limited safety data with children, young people and their parents/guardians. Any vaccination would need to be authorised by a prescriber (usually a doctor). We would expect that this discussion would take into account: 

• the frequency and severity of respiratory infection, and
• the history of hospital admissions, particularly the risk of or previous admissions to paediatric intensive care due to respiratory tract infections.

It is important to stress that at this time the JCVI consider that there are no data to support use of the vaccine in younger age groups or other clinical groups.

• 1. Those who are clinically extremely vulnerable will be eligible for vaccination in priority group 4 (after those aged 75 and over). Those with other clinical vulnerabilities specified by the JCVI will be eligible for the vaccine in priority group 6 (after those aged 65 and over). For further details see: www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020/joint-committee-on-vaccination-and-immunisation-advice-on-priority-groups-for-covid-19-vaccination-30-december-2020
• 2. The Green Book, chapter 14a, version 7, published 12 February 2021 assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961287/Greenbook_chapter_14a_v7_12Feb2021.pdf
• 3. The Green Book, chapter 14a, version 5 (published 21 January 2021)
• 4. The Pfizer BioNTech vaccine is authorised for 16 years and over, the AstraZeneca vaccine for 18 years and over.

Sue Protheroe
BSPGHAN President April 7^th 2021

March 2021 Highlights

by BSPGHAN | Mar 28, 2021 | News

Dear members 

I hope this email finds you all well. 

I trust that you are looking forward to our BSPGHAN Annual Meeting 27-29th April. If you already registered for January, there's no need to re-register for April.  A reminder that accepted abstracts will be published in Frontline Gastroenterology.

I hope that you are making regular use of your access to the journal and enjoying the brilliant educational material that is accessed via our members login page? 

Please see Highlights for Members – Publishing Papers to Impact on Practice for March 2021 sent from the Editor in Chief, Professor Mark Beattie.  

Best wishes 

Sue  BSPGHAN President. 

Dear Colleagues 

I wanted to highlight some of our recent published content that I thought would be of interest 

The gut microbiome: what every gastroenterologist needs to know

https://fg.bmj.com/content/12/2/118

Getting to grips with sarcopenia: recent advances and practical management for the gastroenterologist

https://fg.bmj.com/content/12/1/53

Diagnostic ileocolonoscopy: getting the basics right

https://fg.bmj.com/content/11/6/484

Refeeding syndrome : physiological background and practical management

https://fg.bmj.com/content/11/5/404

British Society of Gastroenterology (BSG)-led multisociety consensus care bundle for the early clinical management of acute upper gastrointestinal bleeding

https://fg.bmj.com/content/11/4/311

Also online first

How to manage a high-output stoma

https://fg.bmj.com/content/early/2021/03/22/flgastro-2018-101108

Short bowel syndrome in infancy: recent advances and practical management

https://fg.bmj.com/content/early/2020/12/16/flgastro-2020-101457

Gut-focused hypnotherapy for children and adolescents with irritable bowel syndrome

https://fg.bmj.com/content/early/2020/11/22/flgastro-2020-101679

Exit strategies from the COVID-19 lockdown for children and young people receiving home parenteral nutrition (HPN): lessons from the BSPGHAN Intestinal Failure Working Group experience

https://fg.bmj.com/content/early/2020/10/26/flgastro-2020-101598

Eosinophilic oesophagitis: recent advances and practical management

https://fg.bmj.com/content/early/2020/09/06/flgastro-2019-101313

Check out the journal – lots of other excellent content across gastroenterology, endoscopy, hepatology and nutrition 

https://fg.bmj.com/

Follow us on twitter https://twitter.com/FrontGastro_BMJ

Check out the blog https://blogs.bmj.com/fg/

Listen to our regular podcasts https://soundcloud.com/bmjpodcasts/sets/frontline-gastroenterology

Check out the instructions for authors – send us your best work – pre submission enquiries welcome https://fg.bmj.com/pages/authors/

Mark Beattie 

Professor RM Beattie

Consultant Paediatric Gastroenterologist

Honorary Professor of Paediatric Gastroenterology and Nutrition

Editor in Chief Frontline Gastroenterology  

Mark.beattie@uhs.nhs.uk

https://fg.bmj.com/

@FrontGastro_BMJ